Mechanistic studies assessing the interaction of APOBEC enzymes with cancer drivers (e.g., MYC) or other factors active in ER negative cancers would allow to quantify the impact on these tumors ́ mutational landscape and define new drug targets or alternative treatment regimens (e.g., PARP1-inhibitors)57. Here, PARP1 is linked to cancer.